Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
151.40
+0.28 (+0.19%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
51
52
Next >
Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
↗
April 25, 2025
Via
Benzinga
Alphabet, Intel And 3 Stocks To Watch Heading Into Friday
↗
April 25, 2025
Via
Benzinga
Which S&P500 stocks are moving after the closing bell on Thursday?
↗
April 24, 2025
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session.
Via
Chartmill
Gilead (GILD) Q1 2025 Earnings Call Transcript
↗
April 24, 2025
Via
The Motley Fool
Topics
Earnings
World Trade
Earnings Scheduled For April 24, 2025
↗
April 24, 2025
Via
Benzinga
P/E Ratio Insights for Gilead Sciences
↗
April 23, 2025
Via
Benzinga
Gilead Sciences Stock Slips After Mixed Q1 Results, Lowered FY25 EPS Guidance
↗
April 24, 2025
Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.
Via
Benzinga
Gilead Sciences (NASDAQ:GILD) Misses Q1 Revenue Estimates
April 24, 2025
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance...
Via
StockStory
Topics
Artificial Intelligence
Gilead Sciences' Bread-And-Butter Drug Missed Sales Views. And It's Not The Only One.
↗
April 24, 2025
Biktarvy sales came in below forecasts. Will Gilead stock be able to shrug it off?
Via
Investor's Business Daily
Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher
↗
April 24, 2025
BriaCell confirms complete resolution of lung metastasis at 4 months in Phase 1/2a trial using Bria-OTS immunotherapy in advanced breast cancer.
Via
Benzinga
Wall Street Rally Extends Into Third Day: What's Driving Markets Thursday?
↗
April 24, 2025
U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade...
Via
Benzinga
Topics
Government
World Trade
Gilead Sciences's Options Frenzy: What You Need to Know
↗
April 23, 2025
Via
Benzinga
Exploring Gilead Sciences's Earnings Expectations
↗
April 23, 2025
Via
Benzinga
Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect
April 23, 2025
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what you need to know.
Via
StockStory
Topics
Artificial Intelligence
Assessing Gilead Sciences: Insights From 15 Financial Analysts
↗
April 22, 2025
Via
Benzinga
Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer
↗
April 21, 2025
Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with no new safety concerns.
Via
Benzinga
Gilead Announces Positive Results From Trodelvy-Keytruda Combo Study For Breast Cancer: But Retail’s Unmoved
↗
April 21, 2025
Triple-negative breast cancer accounts for approximately 15% of all breast cancers and has a higher chance of recurrence.
Via
Stocktwits
Why Quality Investors May Find GILEAD SCIENCES INC (NASDAQ:GILD) Attractive.
↗
April 19, 2025
A fundamental analysis of (NASDAQ:GILD) shows GILEAD SCIENCES INC (NASDAQ:GILD) may be suited for quality investing, we'll explore why in this article.
Via
Chartmill
2 High-Yielding ETFs Retirees Can Safely Build Their Portfolios Around
↗
April 17, 2025
Via
The Motley Fool
Topics
ETFs
Economy
World Trade
Time 100 Most Influential People Includes Elon Musk, Mark Zuckerberg, Alex Karp And More Public Company CEOs
↗
April 16, 2025
The Time 100 list of the most influential people in the world includes Elon Musk, Mark Zuckerberg and several other CEOs of publicly traded companies.
Via
Benzinga
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
↗
April 16, 2025
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating...
Via
Benzinga
Topics
Government
3 Reasons GILD is Risky and 1 Stock to Buy Instead
April 15, 2025
In a sliding market, Gilead Sciences has defied the odds, trading up to $106.42 per share. Its 24% gain since October 2024 has outpaced the S&P 500’s 6.9% drop. This was partly due to its solid...
Via
StockStory
Topics
Stocks
Is Iovance Biotherapeutics a Millionaire-Maker?
↗
April 14, 2025
Via
The Motley Fool
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
↗
April 11, 2025
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.
Via
Benzinga
Topics
Government
World Trade
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
↗
April 10, 2025
Here's why the 90-day tariffs delay doesn't help pharmaceutical companies.
Via
Investor's Business Daily
Topics
Government
Stocks
World Trade
Rule Breaker Investing: Essays From Yesterday, Vol. 7
↗
April 10, 2025
Via
The Motley Fool
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
↗
April 09, 2025
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.
Via
Benzinga
Topics
Government
Supply Chain
World Trade
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
↗
April 09, 2025
The US market session of Wednesday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.
Via
Chartmill
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
↗
April 09, 2025
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.
Via
Investor's Business Daily
Topics
Government
Stocks
World Trade
2 Top Dividend Stocks That Could Set You Up for Life
↗
April 09, 2025
Via
The Motley Fool
Topics
Government
Initial Public Offering
Intellectual Property
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
51
52
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today